Table 1. Baseline characteristics of patients treated with rosuvastatin + mineral supplement or placebo.
| Rosuvastatin + Zn,Se (n = 38) | Rosuvastatin + Placebo (n = 38) | P-value | |
|---|---|---|---|
| Age (years) | 61.7 ± 9.1 | 62.8 ± 9.8 | 0.61 |
| Body mass index (kg/m2) | 28.3 ± 4.5 | 27.8 ± 4.6 | 0.53 |
| Abdominal circumference (cm) | 98.8 ± 10.9 | 97.9 ± 9.9 | 0.29 |
| Sex (male/female) | 24/14 | 23/15 | 0.99 |
| Associated Diseases | |||
| None [n (%)] | 10 (26) | 2 (5) | 0.02 |
| Hypertension [n (%)] | 20 (53) | 28 (74) | |
| Type 2 diabetes mellitus [n (%)] | 2 (5) | 0 (0) | |
| Hypertension + Type 2 diabetes mellitus [n (%)] | 6 (16) | 8 (21) | |
| Number of atherosclerotic lesions ≥60% | |||
| 1 [n (%)] | 20 (53) | 18 (47) | 0.94 |
| 2 [n (%)] | 12 (32) | 12 (32) | |
| 3 [n (%)] | 4 (10) | 6 (16) | |
| ≥4 [n (%)] | 2 (5) | 2 (5) | |
| Previous coronary or cerebral ischemic events | |||
| None [n (%)] | 25 (66) | 21 (55) | 0.06 |
| Acute myocardial infarction [n (%)] | 12 (31) | 15 (40) | |
| Ischemic vascular cerebral accident [n (%)] | 1 (3) | 2 (5) | |
| Use of medication prior randomization | |||
| Statins (simvastatin) [n (%)] | 19 (50) | 13 (34) | 0.12 |
| Antiplatelet [n (%)] | 38 (100) | 38 (100) | |
| Antihypertensive [n (%)] | 38 (100) | 38 (100) |
Age, body mass index and abdominal circumference: data are mean ± standard deviation.